Abstract: Disclosed is a method for producing, among others, alkenes and/or saturated or unsaturated oxygenates and, which include at least one of an aldehyde and an acid, comprising subjecting the corresponding C3 to C5 aliphatic alcohols that are derivable from biomass, to a vapor phase process over the catalytic system in the presence of a gas mixture of oxygen, air or nitrogen and/or other suitable diluting gas. The catalyst system comprises multi-catalytic zones, in each of which the composition of the co-feed and other reaction parameter can be independently controlled.

Abstract: Disclosed is a catalyst system, its methods of preparation and its use for producing, among others, alkenes and/or saturated or unsaturated oxygenates and, which include at least one of an aldehyde and an acid (such as propyl aldehyde, acrolein, acrylic acid, isobutyl aldehyde, methacrolein, methacrylic acid), comprising subjecting the corresponding C3 to C5 aliphatic alcohols that are derivable from biomass, such as, propanols, propanediols, and isobutanol, to a vapor phase process over the catalytic system described herein in the presence of a gas mixture of oxygen, air or nitrogen and/or other suitable diluting gas. In the case where a C3 aliphatic alcohol (1-propanol, 2-propanol, or 1,2-propanediol or 1,3-propanediol) or a mixture thereof is subjected to a vapor phase catalytic process over the said catalytic system in the presence of air or oxygen, and a co-fed gas, such as nitrogen or other diluting gas, the product is at least one of propylene, propyl aldehyde, acrolein and acrylic acid.

Abstract: The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.

Abstract: The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.

Abstract: The present invention is directed toward a GGTase-I competitive binding assay which can be used to determine the relative GGTase-I inhibitory potency of test compounds. The present invention is also directed toward radiolabeled geranylgeranyl-protein transferase type-I inhibitor compounds which are useful to label GGTase-I in assays, whether cell-based, tissue-based or in whole animal.

Abstract: The present invention is directed toward radiolabeled farnesyl-protein transferase inhibitor compounds which are useful to label FPTase in assays, whether cell-based, tissue-based or in whole animal. The tracers can also be used in competitive binding assays to obtain information on the interaction of unlabeled FTIs with FPTase.

Abstract: This invention concerns the short synthesis of 5,6-dihydro-(S)-4-(ethylamino)-(S)-6-[C.sup.3 H.sub.3 ]-4H-thieno [2,3-b]thiopyran-2-sulfonamide 7,7-dioxide and related non-radioactive and radioactive compounds. The key step is the regioselective and stereo-controlled methylation of the C-6 (.alpha.-sulfone) carbanion in the presence of the monoprotected sulfonamide anion.